Brief: Cidara Therapeutics- Estimates Will Incur Charges Of About $1.2 Million For Severance Payments And Employee Benefits, Primarily In Q4 2024
12/09/2024 22:56
Cidara Therapeutics Inc CDTX.O :
* CIDARA THERAPEUTICS- ESTIMATES WILL INCUR CHARGES OF ABOUT
$1.2
MILLION FOR SEVERANCE PAYMENTS AND EMPLOYEE BENEFITS, PRIMARILY
IN Q4 2024
* CIDARA THERAPEUTICS INC: EXPECTS TO INITIATE PHASE 2B
CLINICAL
TRIAL OF CD388 FOR PREVENTION OF INFLUENZA IN Q3 2024
Source text for Eikon: ID:n0001610618-24-000121
Further company coverage: CDTX.O
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade